Argus Panoptes

Hypergiant Industries Partners With Trive Capital

Retrieved on: 
Tuesday, August 22, 2023
Technology, Contracts, Satellite, Other Technology, Military, Software, Government Technology, Data Management, Defense, Artificial Intelligence, Cloud, Colossal Biosciences, Private sector, Argus Panoptes, National Aeronautic Association, National Reconnaissance Office, Amazon Elastic Compute Cloud, Hypergiant Industries, GPG, Partnership, USAF, Life, CBC2, Multimedia, United States Space Force, Invention, Public sector, Organization, Amazon, Acquisition, NASA, Heel, United States Department of the Army, Capital, RET, Command, Ground Intelligence Officer, Artificial intelligence, Growth, United States Secretary of Homeland Security, United States Department of the Air Force, AWS, Risk management, Renewable energy, Video game, Boeing, Nat Trives, Hypergiant

Trive Capital , a Dallas-based private equity firm, announces the acquisition of artificial intelligence (AI) defense platform and solutions company, Hypergiant Industries , to complement its current portfolio company, Forward Slope.

Key Points: 
  • Trive Capital , a Dallas-based private equity firm, announces the acquisition of artificial intelligence (AI) defense platform and solutions company, Hypergiant Industries , to complement its current portfolio company, Forward Slope.
  • Mike Betzer, the Chief Executive Officer (CEO) of Hypergiant, will continue leading the company into its next phase of accelerated growth.
  • David Stinnett, Partner at Trive Capital, commented, “Hypergiant’s unique geospatial data visualization capability has positioned the company at the leading edge of C5ISR technologies that address mission-critical defense priorities.
  • Hypergiant now has over 150 employees and contractors, and its investors include lead investor Align Capital, along with GPG, Perot Jain, Beringer Capital, and Capital Factory.

George Washington knew when it was time to go, unlike Trump, because the founders worried about the judgment of history

Retrieved on: 
Wednesday, August 2, 2023
People, Biography, Awareness, Private, Friends, Public opinion, Revolution, Public, Person, Embarrassment, Judgement, Man, Party, Time, American Revolution, Crime, Diagnosis, Argus Panoptes, Character, Cosmetics, Management, Bridge

But even if he’s not, a set of deeper issues has clearly emerged already: Many leaders and politicians today just cling to power.

Key Points: 
  • But even if he’s not, a set of deeper issues has clearly emerged already: Many leaders and politicians today just cling to power.
  • Heedless of the common good, they seem to forget that the judgment of posterity will come, inescapably.
  • One clear diagnosis of this problem came almost 40 years ago from Robert Bellah, the renowned American sociologist, when he spotted a momentous transformation.
  • People, especially public figures, were highly concerned about their reputation, or “character,” as it was usually called.

Honeymoon turns to hatred

    • When Washington was about to enter the presidency, he realized his moral stature would suffer.
    • “The eyes of Argus are upon me,” he wrote to his nephew Bushrod Washington in July 1789.
    • “I know well that no man will ever bring out of that office the reputation which carries him into it,” he wrote.
    • At the same time, none of them tried to cling to the role of leader when their time had passed.

Stepping down

    • In June 1799, Jonathan Trumbull Jr., the governor of Connecticut who had also served as Washington’s military secretary during the American Revolution, urged him to run for a third term.
    • Many others had previously prodded him.
    • Even if he were willing to run for president again, “I am thoroughly convinced I should not draw a single vote” from the opposite side, he wrote Trumbull.

Retiring from public life

    • They stayed away from public controversy as much as they could.
    • And when they believed they were done, they retired from the public scene – a political act in its own terms.
    • Relinquishing power and retiring were the best way to ensure Washington’s glory and reputation.

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 15, 2021
Photorefractive keratectomy, Wound healing, PK, Safety, DHODH, Argus Panoptes, Private Securities Litigation Reform Act, IgG4-related ophthalmic disease, NASDAQ, CEO, Macular degeneration, Inflammation, Risk, Geographic atrophy, Annual report, Dihydroorotate dehydrogenase, Acquisition, Company, Research, GLOBE, Retinitis pigmentosa, Eye, SEC, Ophthalmology, SALT, Light, Marketing, Patient, Retinal ganglion cell, FDA, Brain, Pharmaceutical industry, Vaccine, Animal

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (Kiora or the Company) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities.

Key Points: 
  • SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (Kiora or the Company) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities.
  • Raised gross proceeds of $10.75 million through a registered direct offering in August to strengthen the companys financial position.
  • Anticipated milestones include:
    Report topline data in fourth quarter of 2021 on a Ph1/2a safety, PK and exploratory ocular surface inflammation (dry eye) trial.
  • Kioras results may also be affected by factors of which Kiora is not currently aware.

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 12, 2021
Income, Argus Panoptes, NASDAQ, Degenerative disease, DED, Paycheck Protection Program, Letter, Drug development, Research, Company, Private Securities Litigation Reform Act, Common stock, Duane syndrome, GLOBE, Forgiveness, SEC, Ophthalmology, Acquisition, Epithelium, Marketing, Medicare Part D, Cornea, Patient, Â, Growth, Medicare, Conjunctivitis, DHODH, Dihydroorotate dehydrogenase, Risk, OBG, Regenerative medicine, Eye, Pharmaceutical industry, Medical device, Management, Tutoring

In the second quarter of 2021 we made significant advancements to build our business and our clinical initiatives remain on track as we enter this new phase of continued growth, said Brian Strem, Ph.D., President and Chief Executive Officer of EyeGate.

Key Points: 
  • In the second quarter of 2021 we made significant advancements to build our business and our clinical initiatives remain on track as we enter this new phase of continued growth, said Brian Strem, Ph.D., President and Chief Executive Officer of EyeGate.
  • Report top-line data from the proof-of-concept study in Austria for patients with DED in Q4 2021.
  • During the second quarter of 2021, the Company recorded a gain of $0.278 million due to the full forgiveness of loan funds received under the Paycheck Protection Program.
  • EyeGates results may also be affected by factors of which EyeGate is not currently aware.

EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 12, 2021
Ophthalmology, Health, Clinical medicine, Eye drop, Ophthalmic drug administration, Dry eye syndrome, Ophthalmic, Cost, Conjunctivitis, Argus Panoptes

PP-001 has been successfully formulated as an ophthalmic eye drop for conjunctivitis and dry eye disease (\xe2\x80\x9cDED\xe2\x80\x9d).

Key Points: 
  • PP-001 has been successfully formulated as an ophthalmic eye drop for conjunctivitis and dry eye disease (\xe2\x80\x9cDED\xe2\x80\x9d).
  • The increase of $0.342 million was primarily due to increases in personnel related costs from the Panoptes acquisition, OBG manufacturing costs, and development costs for PP-001.
  • EyeGate\xe2\x80\x99s results may also be affected by factors of which EyeGate is not currently aware.
  • The forward-looking statements in this press release speak only as of the date of this press release.